Accessibility Menu
 
Bio-Rad Laboratories logo

Bio-Rad Laboratories

(NYSE) BIO

Current Price$272.33
Market Cap$7.15B
Since IPO (1980)+10,270%
5 Year-51%
1 Year+6%
1 Month+0%

Bio-Rad Laboratories Financials at a Glance

Market Cap

$7.15B

Revenue (TTM)

$2.58B

Net Income (TTM)

$759.90M

EPS (TTM)

$27.92

P/E Ratio

9.49

Dividend

$0.00

Beta (Volatility)

0.94 (Low)

Price

$272.33

Volume

543,684

Open

$261.29

Previous Close

$272.12

Daily Range

$260.58 - $273.79

52-Week Range

$211.43 - $343.12

BIO: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Bio-Rad Laboratories

Industry

Life Sciences Tools and Services

Employees

7,400

CEO

Norman D. Schwartz

Headquarters

Hercules, CA 94547, US

BIO Financials

Key Financial Metrics (TTM)

Gross Margin

52%

Operating Margin

9%

Net Income Margin

29%

Return on Equity

11%

Return on Capital

2%

Return on Assets

7%

Earnings Yield

10.54%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$7.15B

Shares Outstanding

26.99M

Volume

543.68K

Short Interest

0.00%

Avg. Volume

264.99K

Financials (TTM)

Gross Profit

$1.34B

Operating Income

$270.50M

EBITDA

$475.90M

Operating Cash Flow

$532.20M

Capital Expenditure

$157.60M

Free Cash Flow

$374.60M

Cash & ST Invst.

$1.54B

Total Debt

$1.53B

Bio-Rad Laboratories Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$693.20M

+3.9%

Gross Profit

$345.20M

+1.0%

Gross Margin

49.80%

N/A

Market Cap

$7.15B

N/A

Market Cap/Employee

$928.89K

N/A

Employees

7,700

N/A

Net Income

$720.00M

+200.6%

EBITDA

$114.30M

+113.5%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$11.70M

-96.0%

Accounts Receivable

$472.50M

+4.4%

Inventory

$740.70M

-2.5%

Long Term Debt

$1.49B

+12.1%

Short Term Debt

$37.90M

-11.7%

Return on Assets

7.18%

N/A

Return on Invested Capital

2.28%

N/A

Free Cash Flow

$119.10M

+46.6%

Operating Cash Flow

$164.90M

+32.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HQYHealthEquity, Inc.
$82.10+0.56%
CRLCharles River Laboratories International, Inc.
$159.19+0.75%
GRFSGrifols, S.A.
$7.60-1.17%
ATRAptarGroup, Inc.
$124.15+0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$43.62-0.02%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$7.61+0.00%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$13.00+0.01%
QQQInvesco QQQ Trust
$583.98-0.01%

Questions About BIO

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.